Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jan;31(1):102–104. doi: 10.1111/j.1365-2125.1991.tb03865.x

The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis.

M A Young 1, L Aarons 1, S Toon 1
PMCID: PMC1368420  PMID: 2015160

Abstract

Plasma and synovial fluid concentrations of the enantiomers of flurbiprofen were measured in 15 rheumatoid patients receiving 100 mg racemic flurbiprofen twice daily. Pharmacokinetic parameters showed considerable variability within the group of patients, although differences in S(+)/R(-) plasma concentration ratios were small. The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for R(-)-flurbiprofen were 0.075 (+/- 0.066) l min-1, 12.47 (+/- 5.79) l and 138 (+/- 61) min, respectively. The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for S(+)-flurbiprofen were 0.057 (+/- 0.035) l min-1, 12.81 (+/- 4.43) l and 155 (+/- 49) min, respectively. S(+)/R(-) ratios (+/- s.d.) rose from 1.06 (+/- 0.12) to 1.75 (+/- 0.61) at the end of the 12 h interval in plasma and from 1.18 (+/- 0.13) to 1.47 (+/- 0.24) over the measured time course in synovial fluid. Increases in S(+)/R(-) ratios may be clinically important as they demonstrate accumulation of the pharmacologically active species.

Full text

PDF
102

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons L., Salisbury R., Alam-Siddiqi M., Taylor L., Grennan D. M. Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. Br J Clin Pharmacol. 1986 Feb;21(2):155–163. doi: 10.1111/j.1365-2125.1986.tb05170.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adams S. S., Bresloff P., Mason C. G. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J Pharm Pharmacol. 1976 Mar;28(3):256–257. doi: 10.1111/j.2042-7158.1976.tb04144.x. [DOI] [PubMed] [Google Scholar]
  3. Adams S. S., Burrows C. A., Skeldon N., Yates D. B. Inhibition of prostaglandin synthesis and leucocyte migration by flurbiprofen. Curr Med Res Opin. 1977;5(1):11–16. doi: 10.1185/03007997709108969. [DOI] [PubMed] [Google Scholar]
  4. Ariëns E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol. 1984;26(6):663–668. doi: 10.1007/BF00541922. [DOI] [PubMed] [Google Scholar]
  5. Ariëns E. J., Wuis E. W. Bias in pharmacokinetics and clinical pharmacology. Clin Pharmacol Ther. 1987 Oct;42(4):361–363. doi: 10.1038/clpt.1987.163. [DOI] [PubMed] [Google Scholar]
  6. Caldwell J., Hutt A. J., Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol. 1988 Jan 1;37(1):105–114. doi: 10.1016/0006-2952(88)90762-9. [DOI] [PubMed] [Google Scholar]
  7. Caldwell J., Winter S. M., Hutt A. J. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica. 1988 Jan;18 (Suppl 1):59–70. [PubMed] [Google Scholar]
  8. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association. Ann Rheum Dis. 1959 Mar;18(1):49–53. [PMC free article] [PubMed] [Google Scholar]
  9. Drayer D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther. 1986 Aug;40(2):125–133. doi: 10.1038/clpt.1986.150. [DOI] [PubMed] [Google Scholar]
  10. Grennan D. M., Aarons L., Siddiqui M., Richards M., Thompson R., Higham C. Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol. 1983 Mar;15(3):311–316. doi: 10.1111/j.1365-2125.1983.tb01504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hutt A. J., Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids--a novel route with pharmacological consequences. J Pharm Pharmacol. 1983 Nov;35(11):693–704. doi: 10.1111/j.2042-7158.1983.tb02874.x. [DOI] [PubMed] [Google Scholar]
  12. Kaiser D. G., Vangiessen G. J. GLC determination of ibuprofen ((plus or minus)-2-(p-isobutylphenyl)propionic acid) in plasma. J Pharm Sci. 1974 Feb;63(2):219–221. doi: 10.1002/jps.2600630208. [DOI] [PubMed] [Google Scholar]
  13. Maître J. M., Boss G., Testa B. High-performance liquid chromatographic separation of the enantiomers of anti-inflammatory 2-arylpropionates: suitability of the method for in vitro metabolic studies. J Chromatogr. 1984 Sep 21;299(2):397–403. doi: 10.1016/s0021-9673(01)97855-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES